Trisha Zeidan, MD
Endocrinology, Diabetes & Metabolism · Dayton, OHNPI 1679695985
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $105,279 of the $124,415 with a category attached, or 84.6%. 20 manufacturers reported payments, led by Lilly USA, LLC at 46.1% of the total. Reporting peaked in 2023 at $49,025 and has fallen 95.6% since, to $2,178 in 2025. Among endocrinology, diabetes & metabolism clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 246 payments — averaging $505.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$57K
- Novo Nordisk$25K
- Valeritas, Inc.$10K
- Boehringer Ingelheim$10K
- Zealand Pharma US, Inc.$7K
- Mannkind Corporation$7K
- plus $8K from 14 others
What the payments were for
- Consulting fees$5,3054%
- Speaking & faculty fees$105,27985%
- Travel & lodging$6,5415%
- Food & beverage$7,1566%
- Education$840%
- Other$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 91 | $57,307 |
| Novo Nordisk | 37 | $25,292 |
| Valeritas, Inc. | 18 | $9,916 |
| Boehringer Ingelheim | 24 | $9,867 |
| Zealand Pharma US, Inc. | 10 | $6,997 |
| Mannkind Corporation | 10 | $6,736 |
| Abbott | 7 | $3,266 |
| Corcept Therapeutics | 7 | $1,915 |
| Cequr Corporation | 4 | $1,233 |
| BETA Bionics, Inc. | 7 | $522 |
| Medtronic | 7 | $355 |
| Xeris Pharmaceuticals, Inc. | 2 | $229 |
| Bayer | 2 | $203 |
| AstraZeneca(2 entities) | 3 | $193 |
| Dexcom, Inc. | 4 | $150 |
| Tandem Diabetes Care, Inc. | 4 | $70 |
| Amgen | 4 | $69 |
| Amphastar Pharmaceuticals, Inc. | 2 | $42 |
| Insulet Corporation | 2 | $36 |
| Ascensia Diabetes Care US Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$37,692
- JARDIANCE$26,744
- V-GO$21,006
- Ozempic$12,708
- RYBELSUS$9,879
- FreeStyle Libre Pro$3,017
- ZEGALOGUE$2,240
- Korlym$1,880
- iLet Bionic Pancreas$1,286
- CeQur Simplicity$1,162
- iLet Insulin Infusion Kit Inset$429
- iLet Insulin Infusion Kit Contact Detach$429
- GVOKE HYPOPEN$229
- Kerendia$122
- MINIMED 770G$104
How this compares
$124,415 in reported general payments places this provider in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 14 | $1,209,003 |
| OzempicSemaglutide | 224 | $368,244 |
| TrulicityDulaglutide | 140 | $189,578 |
| JardianceEmpagliflozin | 165 | $181,140 |
| MounjaroTirzepatide | 110 | $140,529 |
| FarxigaDapagliflozin Propanediol | 79 | $105,776 |
| Humalog Kwikpen U-200Insulin Lispro | 31 | $62,791 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 43 | $57,840 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $55,814 |
| ForteoTeriparatide | 13 | $55,267 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 63 | $50,337 |
| TymlosAbaloparatide | 15 | $39,298 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 44 | $37,610 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $34,249 |
| Xigduo XrDapaglifloz Propaned/Metformin | 36 | $32,224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $1,915 | $1,209,00314 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Forteo, Lyumjev, Humalog | $57,307 | $414,290304 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $25,292 | $387,472247 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Glyxambi | $9,867 | $290,896272 claims |
| AstraZenecaFarxiga | $193 | $105,77679 claims |
| Cequr CorporationCequr Simplicity | $1,233 | $6,92812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Dayton
- Deepak SarwalDayton$13K
- Elena ChristofidesColumbus$2.3M
- Kevin PantaloneCleveland$1.2M
- John PaesWesterville$671K
- Samuel AndersonColumbus$556K
- Bhaskar GundaboluToledo$471K
- Nelson WattsCincinnati$346K
- Baker MachhadiehHamilton$304K
- Brian BurtchMentor$264K
- Allan KennedyCleveland$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.